Eshak Goubaa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eshak Goubaa has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Anichavezhi Devendran
School of Biological Sciences, University of Essex, Colchester CO4 3SQ, UK
1 shared publication - Jamal Bouitbir
Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
1 shared publication - Mohamed J. Nsaibia
Department of Cell Biology and Molecular Medicine, Rutgers University, Newark, NJ 07103, USA
1 shared publication - Rihab Bouchareb
Department of Translational Research, Temple University, Philadelphia, PA 19140, USA
1 shared publication - Romain Capoulade
Nantes Université, CHU Nantes, CNRS, INSERM, l’institut du thorax , Nantes F-44000
1 shared publication
Latest Publications
- Open Access
- 10 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3331
Implication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Calcific Aortic Valve Disease (CAVD) is a fibrocalcific disease. Lipoproteins and oxidized phospholipids play a substantial role in CAVD; the level of Lp(a) has been shown to accelerate the progression of valve calcification. Indeed, oxidized phospholipids carried by Lp(a) into the aortic valve stimulate endothelial dysfunction and promote inflammation. Inflammation and growth factors actively promote the synthesis of the extracellular matrix (ECM) and trigger an osteogenic program. The accumulation of ECM proteins promotes lipid adhesion to valve tissue, which could initiate the osteogenic program in interstitial valve cells. Statin treatment has been shown to have the ability to diminish the death rate in subjects with atherosclerotic impediments by decreasing the serum LDL cholesterol levels. However, the use of HMG-CoA inhibitors (statins) as cholesterol-lowering therapy did not significantly reduce the progression or the severity of aortic valve calcification. However, new clinical trials targeting Lp(a) or PCSK9 are showing promising results in reducing the severity of aortic stenosis. In this review, we discuss the implication of lipids in aortic valve calcification and the current findings on the effect of lipid-lowering therapy in aortic stenosis.
- 10 June 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (12) , 3331
Open AccessImplication of Lipids in Calcified Aortic Valve Pathogenesis: Why Did Statins Fail?
Calcific Aortic Valve Disease (CAVD) is a fibrocalcific disease. Lipoproteins and oxidized phospholipids play a substantial role in CAVD; the level of Lp(a) has been shown to accelerate the progression of valve calcification. Indeed, oxidized phospholipids carried by Lp(a) into the aortic valve stimulate endothelial dysfunction and promote inflammation. Inflammation and growth factors actively promote the synthesis of the extracellular matrix (ECM) and trigger an osteogenic program. The accumulation of ECM proteins promotes lipid adhesion to valve tissue, which could initiate the osteogenic program in interstitial valve cells. Statin treatment has been shown to have the ability to diminish the death rate in subjects with atherosclerotic impediments by decreasing the serum LDL cholesterol levels. However, the use of HMG-CoA inhibitors (statins) as cholesterol-lowering therapy did not significantly reduce the progression or the severity of aortic valve calcification. However, new clinical trials targeting Lp(a) or PCSK9 are showing promising results in reducing the severity of aortic stenosis. In this review, we discuss the implication of lipids in aortic valve calcification and the current findings on the effect of lipid-lowering therapy in aortic stenosis.